Inventor profile of:

Michael R. Robinson

City:

Irvine, California

Country:

United States

Published Applications:

64

Last publication date:

2020-08-20

Top Assignees for applications by Michael R. Robinson

The entities that hold a legal rights for patent applications filed by inventor Robinson Michael R.:

Recent patent applications by Robinson Michael R.

Michael R. Robinson from Irvine, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2020-08-20
US20200261358A1
Human necessities

BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS

#2 | 2020-04-23
US20200121593A1
Human necessities

INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS

#3 | 2020-03-05
US20200069847A1
Human necessities

Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof

#4 | 2019-11-07
US20190336441A1
Human necessities

METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION

#5 | 2019-08-22
US20190254965A1
Human necessities

INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS

#6 | 2017-08-03
US20170216414A1
Human necessities

Dermal filler

#7 | 2017-04-13
US20170100334A1
Human necessities

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

#8 | 2017-03-16
US20170071853A1
Human necessities

Intracameral sustained release therapeutic agent implants

#9 | 2017-03-02
US20170056412A1
Human necessities

Prostamide-containing intraocular implants and methods of use thereof

#10 | 2016-09-08
US20160256382A1
Human necessities

SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY

#11 | 2016-07-14
US20160199387A1
Human necessities

Prostamide-containing intraocular implant

#12 | 2016-02-11
US20160038396A1
Human necessities

Dermal filler

#13 | 2016-02-04
US20160030334A1
Human necessities

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

#14 | 2015-10-08
US20150283150A1
Human necessities

Intracameral sustained release therapeutic agent implants

#15 | 2015-08-27
US20150238687A1
Human necessities

Intraocular implant delivery apparatus and methods of use thereof

#16 | 2015-06-25
US20150174062A1
Human necessities

BIODEGRADABLE DRUG DELIVERY SYSTEM

#17 | 2015-05-28
US20150147406A1
Human necessities

Intraocular Formulation

#18 | 2015-04-30
US20150118279A1
Human necessities

Prostamide-containing intraocular implants and methods of use thereof

#19 | 2015-04-16
US20150104491A1
Human necessities

SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY

#20 | 2015-03-19
US20150080845A1
Human necessities

POLYMER SYSTEM FOR SECURING IMPLANTS IN SYRINGE NEEDLES

#21 | 2014-12-04
US20140356438A1
Human necessities

Peripherally administered viscous formulations

#22 | 2014-11-20
US20140341968A1
Human necessities

Intraocular Drug Delivery Systems

#23 | 2014-11-20
US20140341966A1
Human necessities

STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS

#24 | 2014-10-30
US20140322206A1
Human necessities

Method for treating atrophic age related macular degeneration

#25 | 2014-10-23
US20140314868A1
Human necessities

Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof

#26 | 2014-10-09
US20140302007A1
Human necessities

toxin formulation

#27 | 2014-09-18
US20140271780A1
Human necessities

Prostamide-containing intraocular implant

#28 | 2014-03-27
US20140086974A1
Human necessities

Biodegradable drug delivery systems for the sustained release of proteins

#29 | 2014-02-13
US20140045945A1
Human necessities

Intracameral sustained release therapeutic agent implants

#30 | 2014-01-09
US20140010823A1
Human necessities

METHOD FOR DETERMINING OPTIMUM INTRAOCULAR LOCATIONS FOR DRUG DELIVERY SYSTEMS

#31 | 2013-08-29
US20130225505A1
Chemistry; metallurgy

MUTEINS OF HUMAN TEAR LIPCALIN FOR TREATING NEOVASCULAR DISEASE OF THE ANTERIOR SEGMENT OF THE HUMAN EYE

#32 | 2013-07-04
US20130172353A1
Chemistry; metallurgy

3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors

#33 | 2013-03-21
US20130071349A1
Human necessities

BIODEGRADABLE POLYMERS FOR LOWERING INTRAOCULAR PRESSURE

#34 | 2013-02-14
US20130040895A1
Human necessities

Pharmaceutical Formulations and Methods for Treating Ocular Conditions

#35 | 2013-01-17
US20130017268A1
Human necessities

Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof

#36 | 2013-01-17
US20130017243A1
Human necessities

SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY

#37 | 2012-10-18
US20120263779A1
Human necessities

Biodegradable drug delivery system

#38 | 2012-09-27
US20120245505A1
Human necessities

INTRACAMERAL DEVICES FOR SUSTAINED DELIVERY

#39 | 2012-06-07
US20120141532A1
Human necessities

Botulinum toxin formulation

#40 | 2011-07-28
US20110182966A1
Human necessities

Intracameral sustained release therapeutic agent implants

#41 | 2010-11-04
US20100278898A1
Human necessities

Intraocular pressure reduction with intracameral bimatoprost implants

#42 | 2010-09-30
US20100247606A1
Human necessities

INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS

#43 | 2010-05-20
US20100124565A1
Human necessities

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

#44 | 2010-04-29
US20100104654A1
Human necessities

PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF

#45 | 2010-04-22
US20100098772A1
Human necessities

DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING NEOVASCULARIZATION

#46 | 2010-03-25
US20100074957A1
Human necessities

INTRAOCULAR FORMULATION

#47 | 2010-01-21
US20100015158A1
Human necessities

Method for treating atrophic age related macular degeneration

#48 | 2009-08-06
US20090196905A1
Human necessities

STABILIZATION OF MITOCHONDRIAL MEMBRANES IN OCULAR DISEASES AND CONDITIONS

#49 | 2009-06-18
US20090155314A1
Human necessities

Dermal filler

#50 | 2009-06-11
US20090148527A1
Human necessities

INTRAOCULAR FORMULATION

#51 | 2009-06-04
US20090143348A1
Human necessities

POLYSACCHARIDE GEL COMPOSITIONS AND METHODS FOR SUSTAINED DELIVERY OF DRUGS

#52 | 2009-03-26
US20090082796A1
Human necessities

MODIFIED TENOTOMY SCISSORS WITH CONJUNCTIVA RISERS

#53 | 2009-03-26
US20090081277A1
Human necessities

PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING OCULAR CONDITIONS

#54 | 2009-01-01
US20090004245A1
Human necessities

Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens

#55 | 2008-11-27
US20080292679A1
Human necessities

Biodegradable drug delivery system

#56 | 2008-07-31
US20080181929A1
Human necessities

Method for determining optimum intraocular locations for drug delivery systems

#57 | 2008-06-05
US20080131484A1
Human necessities

Intraocular drug delivery systems

#58 | 2008-04-24
US20080097335A1
Human necessities

OCULAR IMPLANT DELIVERY ASSEMBLIES

#59 | 2008-02-21
US20080044476A1
Human necessities

Peripherally administered viscous formulations

#60 | 2008-02-07
US20080033351A1
Human necessities

Ocular implant delivery assemblies with distal caps

#61 | 2007-12-27
US20070298074A1
Human necessities

Steroid-containing sustained release intraocular implants and related methods

#62 | 2007-12-27
US20070298073A1
Human necessities

Steroid-containing sustained release intraocular implants and related methods

#63 | 2007-09-27
US20070224278A1
Human necessities

LOW IMMUNOGENICITY CORTICOSTEROID COMPOSITIONS

#64 | 2007-08-16
US20070190111A1
Human necessities

OCULAR THERAPEUTIC AGENT DELIVERY DEVICES AND METHODS FOR MAKING AND USING SUCH DEVICES

InventorID:

40360 ⎘